HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anna Guarini Selected Research

Imatinib Mesylate (Gleevec)

1/2020Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript.
1/2018Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.
12/2011Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
4/2011Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anna Guarini Research Topics

Disease

28B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/2023 - 06/2002
25Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
04/2023 - 01/2006
13Residual Neoplasm
02/2023 - 02/2006
12Neoplasms (Cancer)
04/2023 - 09/2006
5Disease Progression
04/2023 - 08/2003
5BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
02/2023 - 12/2009
5Philadelphia Chromosome
01/2023 - 04/2011
4Acute Promyelocytic Leukemia
09/2015 - 04/2007
3Hematologic Neoplasms (Hematological Malignancy)
02/2023 - 02/2008
3Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
02/2023 - 03/2012
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2011 - 09/2006
3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
05/2007 - 01/2003
3Pathologic Complete Response
02/2007 - 02/2002
2Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
04/2023 - 02/2023
2Lymphoma (Lymphomas)
01/2023 - 03/2012
2Lymphoproliferative Disorders (Lymphoproliferative Disorder)
09/2014 - 07/2006
2Leukemia
04/2011 - 06/2002
1Acute Disease
02/2023
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
12/2020
1Hodgkin Disease (Hodgkin's Disease)
06/2017
1Chromosome Aberrations (Chromosome Abnormalities)
12/2015
1Infertility (Sterility)
07/2015
1Trisomy (Trisomies)
12/2014
1Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
01/2014
1Hematologic Diseases (Blood Diseases)
06/2011
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
04/2011
1Spontaneous Remission
07/2009
1Multiple Myeloma
04/2009
1Ataxia Telangiectasia (Louis Bar Syndrome)
04/2009

Drug/Important Bio-Agent (IBA)

7Rituximab (Mabthera)FDA Link
01/2023 - 01/2014
5ibrutinibIBA
12/2022 - 10/2020
5fludarabineIBA
04/2014 - 06/2002
4Dasatinib (BMS 354825)FDA Link
12/2021 - 04/2011
4Phosphotransferases (Kinase)IBA
01/2021 - 01/2003
4Immunoglobulins (Immunoglobulin)IBA
12/2020 - 11/2006
4Tyrosine Kinase InhibitorsIBA
10/2020 - 12/2009
4Imatinib Mesylate (Gleevec)FDA Link
01/2020 - 04/2011
3MicroRNAs (MicroRNA)IBA
04/2015 - 06/2007
3LigandsIBA
07/2014 - 04/2009
3Proteins (Proteins, Gene)FDA Link
04/2014 - 01/2003
3OligonucleotidesIBA
07/2010 - 01/2006
2Cell-Free Nucleic AcidsIBA
02/2023 - 01/2023
2DNA (Deoxyribonucleic Acid)IBA
02/2023 - 05/2014
2Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2011
2blinatumomabIBA
12/2021 - 10/2020
2Immunoglobulin M (IgM)IBA
04/2015 - 08/2008
2Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA
09/2014 - 10/2012
2Monoclonal AntibodiesIBA
01/2014 - 06/2011
2AntigensIBA
10/2011 - 03/2007
2Sialic Acid Binding Ig-like Lectin 3IBA
10/2011 - 03/2007
2NucleophosminIBA
10/2011 - 09/2006
2Tyrosine (L-Tyrosine)FDA Link
04/2011 - 01/2003
2Protein Kinases (Protein Kinase)IBA
07/2010 - 06/2010
2Tretinoin (Retinoic Acid)FDA LinkGeneric
12/2008 - 04/2007
1tisagenlecleucelIBA
04/2023
1Chimeric Antigen ReceptorsIBA
04/2023
1PromegaIBA
02/2023
1venetoclaxIBA
01/2023
1pegaspargase (Oncaspar)FDA Link
01/2023
1ribonucleotide polymeraseIBA
01/2023
1Agammaglobulinaemia Tyrosine KinaseIBA
01/2021
1ElementsIBA
12/2020
1Drug CombinationsIBA
01/2019
1Dihydrotachysterol (AT 10)IBA
06/2017
1OF 4680IBA
06/2017
1RNA (Ribonucleic Acid)IBA
01/2016
1MTOR InhibitorsIBA
01/2016
1MitogensIBA
12/2015
1EndotoxinsIBA
07/2015
1CD34 Antigens (CD34 Antigen)IBA
11/2014
1Natural Killer Cell ReceptorsIBA
07/2014
1Neutralizing AntibodiesIBA
07/2014
1Chlorambucil (Leukeran)FDA Link
05/2014
1Cadherins (E-Cadherin)IBA
04/2014
1Alemtuzumab (Campath)FDA Link
02/2014
1NucleotidesIBA
11/2013
1nutlin 3IBA
11/2013
1Immunoglobulin D (IgD)IBA
04/2013
1Mevalonic Acid (Mevalonate)IBA
10/2012
1Oxidoreductases (Dehydrogenase)IBA
03/2012
1RNA Splicing FactorsIBA
12/2011
1Therapeutic UsesIBA
10/2011
1AntibodiesIBA
10/2011
1CD19 AntigensIBA
06/2011
1Polycomb Repressive Complex 2IBA
05/2011
1Histone MethyltransferasesIBA
05/2011
1Immunoglobulin Variable RegionIBA
04/2011
1Protein Kinase InhibitorsIBA
06/2010
1Messenger RNA (mRNA)IBA
12/2009
1bcr-abl Fusion ProteinsIBA
12/2009
1Interleukin-4 (Interleukin 4)IBA
07/2009
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2009
1Caffeine (No Doz)FDA LinkGeneric
04/2009
12- morpholin- 4- yl- 6- thianthren- 1- yl- pyran- 4- oneIBA
04/2009

Therapy/Procedure

14Therapeutics
04/2023 - 06/2002
4Drug Therapy (Chemotherapy)
01/2023 - 09/2015
1Cell Transplantation
01/2023
1Radiotherapy
01/2020
1Immunotherapy
06/2011
1Aftercare (After-Treatment)
04/2009